by Marisa Wexler, MS | Feb 3, 2026 | Myeloma News
A treatment regimen combining Darzalex Faspro (daratumumab and hyaluronidase-fihj) with three other medications is now approved in the U.S. for all people newly diagnosed with multiple myeloma. The combination treatment, known as D-VRd, uses Darzalex Faspro alongside...
by Marisa Wexler, MS | Feb 2, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to QTX-2101, an oral formulation of an approved chemotherapy drug, as a potential treatment for acute promyelocytic leukemia (APL), a form of blood cancer. The FDA gives this designation to...
by Marisa Wexler, MS | Jan 30, 2026 | Myeloma News
A first-in-human clinical trial testing RMC-5127, an experimental treatment for people with pancreatic cancer and other cancers marked by a specific genetic mutation called RAS G12V, is now recruiting participants in the U.S. The Phase 1 trial (NCT07349537) is open to...
by Marisa Wexler, MS | Jan 29, 2026 | Myeloma News
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio. The data highlights a potential shift in managing a disease where “immune...
by Marisa Wexler, MS | Jan 28, 2026 | Myeloma News
Treatment with relacorilant plus standard chemotherapy was shown in a clinical trial to significantly improve survival compared with chemo alone for people with hard-to-treat ovarian cancer. That’s according to new data announced by relacorilant’s developer Corcept...
by MM360 Staff | Jan 28, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
